Compare FSBC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBC | TBPH |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.4M | 824.9M |
| IPO Year | 2021 | 2013 |
| Metric | FSBC | TBPH |
|---|---|---|
| Price | $40.78 | $16.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $41.90 | $18.40 |
| AVG Volume (30 Days) | 82.3K | ★ 301.9K |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | 28.32 | ★ 279.13 |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $30.25 | $8.46 |
| Revenue Next Year | $12.30 | N/A |
| P/E Ratio | $46.53 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.26 | $9.04 |
| 52 Week High | $42.26 | $21.03 |
| Indicator | FSBC | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 47.95 |
| Support Level | $39.92 | $16.14 |
| Resistance Level | $41.46 | $17.21 |
| Average True Range (ATR) | 1.05 | 0.40 |
| MACD | -0.10 | -0.06 |
| Stochastic Oscillator | 43.21 | 18.02 |
Five Star Bancorp is a bank holding company that operates in California through its subsidiary, a state-chartered non-member bank. The company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans, and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment: Banking.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.